Datapoint: Libtayo Scores Second Skin Cancer Nod

The FDA last week approved Regeneron Pharmaceuticals, Inc. and Sanofi’s Libtayo for the treatment of advanced basal cell carcinoma (BCC) that has not responded to previous treatment in some patients. The anti-PD-1 inhibitor is the first immunotherapy drug approved to treat BCC. Libtayo was approved for the treatment of metastatic cutaneous squamous cell carcinoma in September 2018, and currently holds preferred placement under the pharmacy benefit for 9% of all covered lives. Libtayo is not covered for 21% of lives.

SOURCE: MMIT Analytics, as of 2/11/21

0 Comments

AIS Health Staff

Related Posts

https://www.mmitnetwork.com/wp-content/uploads/2021/09/wordpress-featured-image-datapoints.jpg
October 26

Datapoint: Oscar Partners With Colorado Health Systems in Statewide Expansion Effort

Read More
https://www.mmitnetwork.com/wp-content/uploads/2021/09/wordpress-featured-image-datapoints.jpg
October 25

Datapoint: Kaiser Dominates 2022 Star Ratings

https://www.mmitnetwork.com/wp-content/uploads/2021/08/post-default-img.jpg
October 18

Datapoint: AmeriHealth Caritas to Enter Exchange Market

Read More

GAIN THERAPEUTIC AREA-SPECIFIC INTEL TO DRIVE ACCESS FOR YOUR BRAND

Sign up for publications to get unmatched business intelligence delivered to your inbox.

subscribe today